Systematic literature review of quality-of-life questionnaires in Waldenström macroglobulinaemia-need for a disease-specific tool.
作者信息
Bristogiannis Sotirios, Khwaja Jahanzaib, Lwin Yadanar, Uppal Encarl, D'Sa Shirley, Kyriakou Charalampia
机构信息
Department of Haematology and Bone Marrow Transplantation Unit Evangelismos Hospital Athens Greece.
Department of Haematology NHS University College London Hospital London UK.
出版信息
EJHaem. 2023 Mar 21;4(2):555-558. doi: 10.1002/jha2.668. eCollection 2023 May.
Abstract
摘要
相似文献
1
Systematic literature review of quality-of-life questionnaires in Waldenström macroglobulinaemia-need for a disease-specific tool.
EJHaem. 2023 Mar 21;4(2):555-558. doi: 10.1002/jha2.668. eCollection 2023 May.
2
[Diffuse large cell lymphoma and colon adenocarcinoma in patient with Waldenström's macroglobulinaemia].
Srp Arh Celok Lek. 2011 Jan-Feb;139(1-2):95-8. doi: 10.2298/sarh1102095r.
3
Rare presentation of Waldenström's macroglobulinaemia requiring bilateral above-knee amputations: a case report.
J Med Case Rep. 2022 Nov 3;16(1):417. doi: 10.1186/s13256-022-03622-1.
4
Treatment and outcome patterns in European patients with Waldenström's macroglobulinaemia: a large, observational, retrospective chart review.
Lancet Haematol. 2018 Jul;5(7):e299-e309. doi: 10.1016/S2352-3026(18)30087-5.
5
Ibrutinib for patients with rituximab-refractory Waldenström's macroglobulinaemia (iNNOVATE): an open-label substudy of an international, multicentre, phase 3 trial.
Lancet Oncol. 2017 Feb;18(2):241-250. doi: 10.1016/S1470-2045(16)30632-5. Epub 2016 Dec 10.
6
Cutaneous Waldenström's macroglobulinaemia.
Clin Exp Dermatol. 2003 Sep;28(5):491-2. doi: 10.1046/j.1365-2230.2003.01325.x.
7
Once-weekly ofatumumab in untreated or relapsed Waldenström's macroglobulinaemia: an open-label, single-arm, phase 2 study.
Lancet Haematol. 2017 Jan;4(1):e24-e34. doi: 10.1016/S2352-3026(16)30166-1. Epub 2016 Dec 1.
8
Waldenstrøm's macroglobulinaemia of the breast detected by colour Doppler ultrasound.
Br J Radiol. 1999 Jan;72(853):82-4. doi: 10.1259/bjr.72.853.10341695.
9
Hypercalcaemia due to calcium binding IgM paraprotein in Waldenström's macroglobulinaemia.
J Clin Pathol. 1995 Oct;48(10):961-2. doi: 10.1136/jcp.48.10.961.
10
Familial Waldenström's macroglobulinaemia: a case report.
S Afr Med J. 1977 Jun 11;51(24):891-2.
引用本文的文献
1
Health-related quality of life in patients with Waldenström macroglobulinemia: results from the ASPEN trial.
Future Oncol. 2024;20(25):1789-1798. doi: 10.1080/14796694.2024.2355079. Epub 2024 Jul 29.
本文引用的文献
1
Patient reported outcome measures in Waldenström macroglobulinaemia: A real-world data analysis from the WMUK Rory Morrison Registry.
EJHaem. 2022 Dec 29;4(1):221-225. doi: 10.1002/jha2.640. eCollection 2023 Feb.
2
IgM monoclonal gammopathies of clinical significance: diagnosis and management.
Haematologica. 2022 Sep 1;107(9):2037-2050. doi: 10.3324/haematol.2022.280953.
3
Ibrutinib Plus Rituximab Versus Placebo Plus Rituximab for Waldenström's Macroglobulinemia: Final Analysis From the Randomized Phase III iNNOVATE Study.
J Clin Oncol. 2022 Jan 1;40(1):52-62. doi: 10.1200/JCO.21.00838. Epub 2021 Oct 4.
4
Combining Ixazomib With Subcutaneous Rituximab and Dexamethasone in Relapsed or Refractory Waldenström's Macroglobulinemia: Final Analysis of the Phase I/II HOVON124/ECWM-R2 Study.
J Clin Oncol. 2022 Jan 1;40(1):40-51. doi: 10.1200/JCO.21.00105. Epub 2021 Aug 13.
5
Quality of life and fear of cancer recurrence in patients and survivors of non-Hodgkin lymphoma.
Psychol Health Med. 2022 Sep;27(8):1649-1660. doi: 10.1080/13548506.2021.1913756. Epub 2021 Apr 30.
6
Copanlisib plus rituximab versus placebo plus rituximab in patients with relapsed indolent non-Hodgkin lymphoma (CHRONOS-3): a double-blind, randomised, placebo-controlled, phase 3 trial.
Lancet Oncol. 2021 May;22(5):678-689. doi: 10.1016/S1470-2045(21)00145-5. Epub 2021 Apr 10.
7
WhiMSICAL: A global Waldenström's Macroglobulinemia patient-derived data registry capturing treatment and quality of life outcomes.
Am J Hematol. 2021 Jun 1;96(6):E218-E222. doi: 10.1002/ajh.26173. Epub 2021 Apr 9.
8
Management of Waldenström macroglobulinemia in 2020.
Hematology Am Soc Hematol Educ Program. 2020 Dec 4;2020(1):372-379. doi: 10.1182/hematology.2020000121.
9
A randomized phase 3 trial of zanubrutinib vs ibrutinib in symptomatic Waldenström macroglobulinemia: the ASPEN study.
Blood. 2020 Oct 29;136(18):2038-2050. doi: 10.1182/blood.2020006844.
10
Health-related quality of life in Waldenstrom Macroglobulinemia and IgM-related disorders: A single institution experience.
Hematol Oncol. 2020 Feb;38(1):111-113. doi: 10.1002/hon.2699. Epub 2019 Dec 18.
Zotero 插件